Solidarity Therapeutics Trial yields conclusive evidence on effectiveness of repurposed drugs for COVID-19 |
Clinical News
eMediNexus Coverage from: 
Solidarity Therapeutics Trial yields conclusive evidence on effectiveness of repurposed drugs for COVID-19

0 Read Comments                

Within just six months’ time, the world’s largest randomized control trial on COVID-19 therapeutics has provided conclusive evidence on the effectiveness of repurposed drugs for the treatment of this viral disease.

Interim results from the Solidarity Therapeutics Trial have suggested that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens seem to have little or no effect on 28-day mortality or in-hospital course of COVID-19 among hospitalized patients.The results of the trial are being reviewed for publication in a medical journal and have been uploaded as preprint at medRxiv at the following link: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1

Newer antiviral drugs, immunomodulators and anti-SARS COV-2 monoclonal antibodies are currently under consideration for evaluation… (WHO, October 15, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now